Aortyx Funding News – Spanish Healthtech Aortyx Secures €13.8M In Series A Round

Aortyx is developing a minimally invasive solution to treat aortic dissection—a serious condition where the inner wall of the aorta tears. Their approach uses a steerable catheter that navigates through the aorta and places a circular patch over the tear.

The patch is made from biodegradable material, which not only seals the tear but also acts as a scaffold to promote new tissue growth.

Read Also - Sefit Health Funding News -Swiss Startup Sefit Health Raises CHF150,000 Funding

Over 50,000 people in Europe experience aortic dissections each year. Aortyx aims to treat at least half of these cases with its first-generation product.

Unlike traditional treatments such as open-heart surgery, stent grafts, or medication to lower blood pressure—often associated with high risks—Aortyx’s method offers a safer, less invasive alternative.

Jordi Martorell, co-founder and CEO of Aortyx, said: Aortic dissections kill more people than car crashes. What we hope to provide is an option that is effective, long-lasting, and respectful with the aorta to treat aortic dissection and other aortic diseases.

The funding round aims to support Aortyx in reaching first-in-human testing within the next two years. The primary users of this new technology will be vascular and cardiothoracic surgeons.

Aortyx was co-founded by researchers from the IQS School of Engineering in Barcelona, along with Dr. Vicenç Riambau, a globally respected vascular surgeon. Dr. Riambau has played a crucial role in guiding the product’s development, sharing the technology at major international conferences, and publishing the first animal trial results in peer-reviewed journals.

The round is led by Ship2B Ventures through the BSocial Impact Fund (backed by Banco Sabadell, the EIF, and AXIS) and Clave Capital via Clave Innohealth (supported by CDTI-Innvierte). Other investors include Nara Capital, the EIC Fund, the CDTI through its SICC Innvierte, angel investors, and a leading global manufacturer of aortic devices.

Jordi Ferrer, Investment Director at Ship2B Ventures, commented: We are backing Aortyx as it potentially represents a revolution in cardiovascular medicine. They are developing a solution that is not only disruptive and technically brilliant, but driven by a clear social purpose: to save lives where today there are barely any options. Led by an exceptional team and a bold vision, they have the potential to forever change how we treat aortic dissections.

The intellectual property (IP) behind Aortyx’s innovation lies in both the catheter deployment system and the patch itself. The bioresorbable patch is made using electrospinning—a technique inspired by the way spiders spin their webs. This method allows the creation of a controlled, viscoelastic, and biocompatible material ideal for medical use.

Sergio San Agustín, Investment Director at Clave Capital and Board Member at Aortyx added: We are extremely excited to join Aortyx. A company born from a vision that will change the paradigm of how aortic dissections are addressed. The technology is the result of years of research at IQS and Hospital Clínic, which have been able to transfer this technology and advance the development of the product for patients with the ultimate goal of saving lives.

The funding will be used to achieve the milestone of first-in-human testing, moving Aortyx’s bioresorbable patch for treating aortic tears one step closer to market launch.

About Aortyx

Founded in 2018 Aortyx is a pioneering medical device company dedicated to advancing vascular repair solutions. Its mission is to provide patients with the most effective treatments using cutting-edge technology.